Mutual of America Capital Management LLC Sells 13,878 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Mutual of America Capital Management LLC trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 166,779 shares of the biotechnology company’s stock after selling 13,878 shares during the quarter. Mutual of America Capital Management LLC owned 0.06% of Exelixis worth $3,748,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Fisher Asset Management LLC increased its position in shares of Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 728 shares during the period. Rise Advisors LLC bought a new stake in Exelixis during the 1st quarter worth approximately $28,000. Park Place Capital Corp purchased a new stake in Exelixis in the 2nd quarter worth approximately $45,000. GAMMA Investing LLC grew its position in shares of Exelixis by 107.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares in the last quarter. Finally, EntryPoint Capital LLC grew its position in shares of Exelixis by 537.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,746 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

NASDAQ:EXEL opened at $26.42 on Monday. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $27.83. The firm has a market cap of $8.01 billion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 0.58 and a beta of 0.54. The business has a 50 day moving average price of $25.20 and a 200-day moving average price of $23.35.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. The business had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Research analysts predict that Exelixis, Inc. will post 1.54 EPS for the current year.

Insider Activity at Exelixis

In other news, EVP Dana Aftab sold 95,000 shares of Exelixis stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the sale, the executive vice president now directly owns 520,990 shares in the company, valued at approximately $13,024,750. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, EVP Dana Aftab sold 95,000 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $25.00, for a total value of $2,375,000.00. Following the completion of the sale, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 20,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00. Following the transaction, the executive vice president now directly owns 630,325 shares in the company, valued at $16,256,081.75. The disclosure for this sale can be found here. Insiders have sold a total of 302,858 shares of company stock worth $7,980,629 in the last 90 days. Company insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $27.00 price objective on shares of Exelixis in a research note on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Exelixis in a report on Wednesday, September 18th. Truist Financial reaffirmed a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. UBS Group initiated coverage on shares of Exelixis in a research note on Thursday. They issued a “neutral” rating and a $30.00 price target for the company. Finally, StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.